The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Gastroenterology. NEJM (https://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice. https://www.nejm.org/action/showPodcastsFeeds NEJM Group Wed, 29 Apr 2026 19:20:41 GMT 2026 NEJM Group en-us 1440 An 86-year-old woman with a history of diabetes and breast cancer was admitted to the hospital with anorexia and weight loss. Imaging revealed multifocal liver lesions. A diagnosis was made. https://www.nejm.org/doi/full/10.1056/NEJMcpc2412525?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcpc2412525 Margaret M. Chapman, Rory L. Cochran, Kumar Krishnan, Kristen M. Hysell, Ahmad Alkashash 2026-04-23 Case 12-2026: An 86-Year-Old Woman with Anorexia, Weight Loss, and Liver Lesions In a phase 1 trial of setidegrasib, a KRAS G12D degrader, 42% of patients had adverse events of grade 3 or higher; 36% of patients with NSCLC and 24% of those with pancreatic cancer had a response. https://www.nejm.org/doi/full/10.1056/NEJMoa2600752?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2600752 Wungki Park, Anup Kasi, Alexander I. Spira, Luis Paz-Ares Rodríguez, Benjamin O. Herzberg, Meredith S. Pelster, Anthony W. Tolcher, Yasutoshi Kuboki, Shigehisa Kitano, Hirokazu Shoji, Judy S. Wang, Jordan D. Berlin, Antoine Hollebecque, Patricia LoRusso, Christos Fountzilas, Philippe A. Cassier, Tomohiro Nishina, Daisuke Sakai, Chiaki Inagaki, Daniel Morgensztern, Makoto Ueno, Minkyu Jung, Sang-We Kim, Pasi A. Jänne, Antoine Italiano, Benoît You, T Macarulla, Hisaki Fujii, Aditya Shetty, Ying Lu, Daniel Cui, Shilpa Kadam, Stanley C. Gill, Junko Toyoshima, Takeshi Saito, Jonathan W. Goldman 2026-04-09 Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer This review summarizes the epidemiology, diagnosis, and management of celiac disease and highlights serologic testing, biopsy confirmation, associated autoimmune conditions, and a gluten-free diet as treatment. https://www.nejm.org/doi/full/10.1056/NEJMcp2415548?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcp2415548 Joseph A. Murray, Steffen Husby 2026-04-09 Celiac Disease An 83-year-old woman with worsening type 2 diabetes presented with a 6-month history of painful rash. Hyperpigmented plaques with coalescing erosions and blisters were seen. Abdominal CT revealed a mass in the tail of the pancreas. https://www.nejm.org/doi/full/10.1056/NEJMicm2516331?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2516331 Jia-An Hung, Ming-Chieh Lin 2026-04-09 Necrolytic Migratory Erythema A 68-year-old man who had undergone intubation 25 days earlier had difficulty swallowing after extubation. A swallowing study showed fluid penetrating into the trachea without triggering a cough reflex (shown in a video). https://www.nejm.org/doi/full/10.1056/NEJMicm2516115?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2516115 Shuo-Ting Jian, Hsiu-Nien Shen 2026-04-09 Silent Aspiration In a 12-year-old boy with severe idiopathic acute necrotizing pancreatitis, CT showed a right portal vein thrombus and a wedge-shaped area of hyperperfusion corresponding to the liver region supplied by the thrombosed vein. https://www.nejm.org/doi/full/10.1056/NEJMicm2516362?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2516362 Tushar Kumar, Sakura M. Noda 2026-04-02 Hepatic Arterial Buffer Response This feature about acute liver failure on the background of alcohol-associated cirrhosis offers a case vignette accompanied by two essays, one recommending liver transplantation and the other supporting medical intensive care management alone. https://www.nejm.org/doi/full/10.1056/NEJMclde2506067?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMclde2506067 Christos P. Kotanidis, Teresa C. Rice, Shimul A. Shah, Emily Bethea, Irun Bhan 2026-04-02 Liver Transplantation in Alcohol-Related Liver Disease Alternative complement pathway overactivation contributes to IgA nephropathy. In a placebo-controlled trial, iptacopan, a complement factor B inhibitor, significantly slowed kidney-function decline in patients with IgA nephropathy. https://www.nejm.org/doi/full/10.1056/NEJMoa2600743?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2600743 Jonathan Barratt, Necmi Eren, Naoki Kashihara, Bart Maes, Dana V. Rizk, Brad Rovin, Hernán Trimarchi, Hong Zhang, Weiming Wang, Ismail Kocyigit, Chuanming Hao, Vladimir Tesař, Kenan Turgutalp, Li Yang, Guangqun Xing, Valter Duro Garcia, Seung Hyeok Han, Wanhong Lu, Antonio Pisani, Julia Weinmann-Menke, Frank Eitner, Nicolas Guerard, Dmytro Butylin, Luca Monaco, Emil Scosyrev, Annabel Magirr, Ronny Renfurm, Thomas Hach, Vlado Perkovic, the APPLAUSE-IgAN Study Group* 2026-03-29 Iptacopan in IgA Nephropathy — Final 24-Month Data In a trial in resected stage III mismatch repair–deficient colon cancer, adding atezolizumab to modified FOLFOX6 improved 3-year disease-free survival, with a higher incidence of grade 3 or 4 toxic effects, mainly fatigue. https://www.nejm.org/doi/full/10.1056/NEJMoa2507874?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2507874 Frank A. Sinicrope, Fang-Shu Ou, Dirk Arnold, Walter R. Peters, Robert J. Behrens, Christopher H. Lieu, Khalid Matin, Deirdre J. Cohen, Samara L. Potter, Andrew B. Nixon, Lisa A Kottschade, Emily Kathol, Wendy L. Frankel, Ardaman Shergill, Dennis Hsu, Anke Reinacher-Schick, Paul Mehan, Philip J. Gold, Maged F. Khalil, Tyler Zemla, Clare Gatten, Eileen M. O’Reilly, Jeffrey A. Meyerhardt 2026-03-26 Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer Corporations that make and market health-harming products are a primary vector for the global increase in mortality related to noncommunicable diseases. Research using internal industry documents can help. https://www.nejm.org/doi/full/10.1056/NEJMms2507028?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMms2507028 Consortium of the Center to End Corporate Harm, University of California, San Francisco 2026-03-26 Corporate Vectors of Chronic Disease — Using Internal Industry Documents to Craft Counterstrategies In countries with organized screening programs for colorectal cancer, 25% of patients who receive a diagnosis have stage III disease with involved regional lymph nodes. Surgery cures only half these patients, and 6 months of fluoropyrimidine-based adjuvant chemotherapy (e.g., intravenous fluorouracil or oral capecitabine) has been the cornerstone of treatment... https://www.nejm.org/doi/full/10.1056/NEJMe2517910?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2517910 Deb Schrag 2026-03-26 ATOMIC Energy — Biomarker-Bespoke Adjuvant Therapy for Colon Cancer A woman with a history of necrotizing pancreatitis presented with abdominal pain and fevers. CT showed a fluid collection with gas and septations in the pancreatic region. A retroperitoneal necrosectomy was performed (shown in a video). https://www.nejm.org/doi/full/10.1056/NEJMicm2515752?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2515752 Zhuo-Long Tu, Jin-Fu Tu 2026-03-26 Walled-Off Pancreatic Necrosis In a phase 3 trial in patients with persistent chemotherapy-induced thrombocytopenia, 84% of those receiving romiplostim had no chemotherapy dose modifications, as compared with 36% of those receiving placebo (odds ratio, 10.16). https://www.nejm.org/doi/full/10.1056/NEJMoa2511882?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2511882 Hanny Al-Samkari, César Muñoz, Çağlayan Geredeli, Ippokratis Korantzis, Beatriz González Astorga, Cagatay Arslan, Johnny Francisco Cordeiro Camargo, Florian Scotté, Giuliano Borges, Kejia Wang, Melissa Eisen, David J. Kuter, Gerald A. Soff 2026-03-12 Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia The IARC Working Group summarizes guidance on H. pylori screen-and-treat programs for gastric cancer prevention and concludes that prevention is the most effective strategy amid a rising global burden. https://www.nejm.org/doi/full/10.1056/NEJMsb2515372?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMsb2515372 Jin Young Park, Yi-Chia Lee, Paul Moayyedi, Iris Lansdorp-Vogelaar, M. Constanza Camargo, Bojan Tepeš, Christian C. Abnet, Il Ju Choi, Gary Clifford, Mario Dinis-Ribeiro, Markus Gerhard, Javier P. Gisbert, Karen J. Goodman, Joo Ha Hwang, Manami Inoue, Violet Kayamba, Marcis Leja, Wai Keung Leung, Wen-Qing Li, Peter Malfertheiner, Zorana Maravic, Tamara Matysiak-Budnik, Melissa McLeod, Francis Megraud, Eileen Morgan, Duco T. Mülder, Julie Parsonnet, Pempa Pempa, Guru Prasad Dhakal, Arnoldo Riquelme, Peter Sasieni, Stella Smith, Janet Takens, Andrea Teng, David Forman 2026-03-12 Helicobacter pylori Screen-and-Treat Programs for Gastric Cancer Prevention — IARC Working Group Report Myelosuppression has long been the major dose-limiting toxic effect of chemotherapy in treating cancer. Reducing the severity of chemotherapy-induced myelosuppression addresses two priorities. One is to prevent myelosuppressive complications — neutropenia and thrombocytopenia, in particular — that can lead to febrile neutropenia, infection, and bleeding. A second priority centers around... https://www.nejm.org/doi/full/10.1056/NEJMe2517578?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2517578 George Goshua, Alfred Ian Lee 2026-03-12 Thrombopoietin-Receptor Agonists in Chemotherapy-Induced Thrombocytopenia Neoadjuvant gemcitabine–oxaliplatin, lenvatinib, and anti–PD-1 antibody led to longer event-free survival than surgery alone in resectable high-risk intrahepatic cholangiocarcinoma, with mainly low-grade adverse events. https://www.nejm.org/doi/full/10.1056/NEJMoa2513918?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2513918 Guo-Ming Shi, Xiao-Yong Huang, Fei Liang, Xiao Liang, Rui Dong, Qing-Hai Ye, Qiang Gao, Yuan Ji, Zheng-Ping Yu, Wen-Long Zhai, Jia-Cheng Lu, Xiao-Wu Li, Fu-Bao Liu, Kui Wang, Wei Yang, Jia-Lin Zhang, Zhi-Qiang Hu, Shuang-Jian Qiu, Xiao-Ying Wang, Xin-Rong Yang, Hui-Chuan Sun, Ying-Hong Shi, Zhen-Bin Ding, Wei-Ren Liu, Xiao-Wu Huang, Cheng Huang, Ying-Hao Shen, Jian Sun, Yi-Feng He, Yuan-Fei Peng, Yang Xu, Jian-Jun Zou, Jian Zhou, Jia Fan, the ZSAB Study Group* 2026-03-05 Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma Group B streptococcal infection mostly affects newborns, infants, pregnant persons, and older adults. Perinatal prevention is successful but contributes to antibiotic exposure. Multivalent glycoconjugate vaccines are in development. https://www.nejm.org/doi/full/10.1056/NEJMra2313146?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMra2313146 Karen M. Puopolo 2026-02-26 Group B Streptococcal Disease Medicare will achieve greater savings on the 15 drugs in its second round of price negotiations than it did in the first round. Despite new challenges, the effort should continue to pay growing dividends. https://www.nejm.org/doi/full/10.1056/NEJMp2517584?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2517584 Benjamin N. Rome, Aaron S. Kesselheim 2026-02-26 The Growing Success of Medicare Drug-Price Negotiation A 60-year-old man presented with a 15-day history of generalized weakness and right upper abdominal pain. Imaging studies revealed diffuse disruption of the hepatic architecture by hyperechoic nodules and areas of necrosis and hemorrhage. https://www.nejm.org/doi/full/10.1056/NEJMicm2514897?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2514897 Nicola Mumoli, Giovanni Serio 2026-02-12 Hepatic Angiosarcoma In two phase 3 trials involving patients with severe hypertriglyceridemia, olezarsen led to a significantly greater reduction in the triglyceride level and in acute pancreatitis events than placebo. https://www.nejm.org/doi/full/10.1056/NEJMoa2512761?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2512761 Nicholas A. Marston, Brian A. Bergmark, Veronica J. Alexander, Thomas A. Prohaska, Yu Mi Kang, Filipe A. Moura, Andre Zimerman, Elaine Waldman, Julia Weinland, Sabina A. Murphy, Erica L. Goodrich, Shuanglu Zhang, Shuting Xia, Dan Li, Anne C. Goldberg, Assen Goudev, Lina Badimon, Robert Gabor Kiss, Michal Vrablik, Daniel Gaudet, Philippe Moulin, Erik S.G. Stroes, Maciej Banach, Hofit Cohen, Dirk Blom, Min-Ji Charng, Børge G. Nordestgaard, Stephen J. Nicholls, Sotirios Tsimikas, Robert P. Giugliano, Marc S. Sabatine, the CORE-TIMI 72a and CORE2-TIMI 72b Investigators 2026-01-29 Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk